VIR - Vir Biotechnology

-

$undefined

N/A

(N/A)

Vir Biotechnology NASDAQ:VIR Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.

Location: | Website: www.vir.bio | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

152.5M

Cash

905.3M

Avg Qtr Burn

-111.6M

Short % of Float

8.43%

Insider Ownership

12.01%

Institutional Own.

76.71%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tobevibart + Elebsiran Details
Infectious disease, Hepatitis Delta Virus

Phase 3

Data readout

Sotrovimab VIR-7831 (GSK4182136) Details
COVID-19, Infectious disease

Phase 3

Update

VIR-3434 +/- VIR-2218 +/- PEG-IFNα Details
Infectious disease, Hepatitis B

Phase 2

Data readout

VIR-3434 + VIR-2218 Details
Infectious disease, Hepatitis B

Phase 2

Data readout

VIR-2482 (Universal prophylaxis) Details
Influenza, Infectious disease

Phase 2

Update

VIR-5818 + Pembrolizumab Details
Cancer, HER2-expressing cancers, Metastatic breast cancer, Metastatic colorectal cancer

Phase 1

Data readout

VIR-5500 Details
Cancer, Castration-resistant prostate cancer

Phase 1

Data readout

VIR-1388 (HVTN 142) Details
Infectious disease, Human immunodeficiency virus, Vaccine

Phase 1

Data readout

VIR-5525 Details
Cancer, Head and neck squamous cell carcinoma, Non-small cell lung carcinoma, Metastatic colorectal cancer

Phase 1

Initiation

Sotrovimab VIR-7831 (GSK4182136) Details
COVID-19, Infectious disease

Failed

Discontinued

VIR-1111 Details
Infectious disease, Human immunodeficiency virus, Vaccine

Failed

Discontinued